[ U.S. DEPARTMENT OF DEFENSE - Autism Research Program Idea Development Award | Research funding ]
Event details
| Date | 01.05.2019 |
| Category | Call for proposal |
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the Autism Research Program (ARP) for 2019. The Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with ASD. This award mechanism is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation.
Projects are required to involve human subjects. Projects that are strictly animal research aimed at developing or refining new technology and research to establish the efficacy/effectiveness of diagnostic agents are not allowed under this funding opportunity. The proposed studies should include early-phase, proof-of-principle studies using human subjects. The proposed studies may be interventional, including Phase 0 clinical trials or single-group intervention studies, and may involve some retrospective data analysis; however, purely retrospective or database-related research is not allowed.
Applications are strongly encouraged to address one of the ARP Areas of Interest. These are listed at the end of this announcement.
Funding: Maximum USD $ 500’000
Duration: 3 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Investigators at the level of Assistant Professor or above are eligible to submit applications.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a list of collaborators and key personnel, a preproposal narrative, and supporting documents as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 01 May 2019, 5:00 p.m. EST (23:00 CET)
Full Application Deadline: 08 August 2018, 11:59 p.m. EST (05:59 09 Aug, CET)
Grants.gov Funding Opportunity Number: W81XWH-19-ARP-IDA
Further information
FY19 ARP areas of interest:
Projects are required to involve human subjects. Projects that are strictly animal research aimed at developing or refining new technology and research to establish the efficacy/effectiveness of diagnostic agents are not allowed under this funding opportunity. The proposed studies should include early-phase, proof-of-principle studies using human subjects. The proposed studies may be interventional, including Phase 0 clinical trials or single-group intervention studies, and may involve some retrospective data analysis; however, purely retrospective or database-related research is not allowed.
Applications are strongly encouraged to address one of the ARP Areas of Interest. These are listed at the end of this announcement.
Funding: Maximum USD $ 500’000
Duration: 3 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Investigators at the level of Assistant Professor or above are eligible to submit applications.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a list of collaborators and key personnel, a preproposal narrative, and supporting documents as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 01 May 2019, 5:00 p.m. EST (23:00 CET)
Full Application Deadline: 08 August 2018, 11:59 p.m. EST (05:59 09 Aug, CET)
Grants.gov Funding Opportunity Number: W81XWH-19-ARP-IDA
Further information
- To see the program announcement, navigate to the search page on Grants.gov and search for the Opportunity Number W81XWH-19-ARP-IDA.
- For questions about the eBRAP or Grants.gov platforms, contact the Research Office.
FY19 ARP areas of interest:
- Assessment of novel therapeutics using valid preclinical models
- Environmental risk factors
- Mechanisms of heterogeneous clinical expression of ASD
- Mechanisms underlying conditions co-occurring with ASD (e.g., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures, eating disorders, pharmacologic side effects, gender dysphoria)
- Factors promoting success in key transitions to independence for individuals living with ASD
- Factors impacting quality of life during geographic relocation, such as military permanent change of station
- Development of healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
- Improve diagnosis and access to services across the life span
- Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services
- Long-term treatment outcomes from previous clinical trials for ASD core symptoms or to alleviate co-occurring conditions
Practical information
- General public
- Free